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Abstract
Prostate cancer remains the single most prevalent cancer in men. Standard therapies are still limited and include
androgen ablation that initially causes tumor regression. However, tumor cells eventually relapse and develop into
a hormone-refractory prostate cancer. One of the current challenges in this disease is to define new therapeutic
targets, which have been virtually unchanged in the past 30 years. Recent studies have suggested that the family
of enzymes known as the proprotein convertases (PCs) is involved in various types of cancers and their progres-
sion. The present study examined PC expression in prostate cancer and validates one PC, namely PACE4, as a
target. The evidence includes the observed high expression of PACE4 in all different clinical stages of human pros-
tate tumor tissues. Gene silencing studies targeting PACE4 in the DU145 prostate cancer cell line produced cells
(cell line 4-2) with slower proliferation rates, reduced clonogenic activity, and inability to grow as xenografts in nude
mice. Gene expression and proteomic profiling of the 4-2 cell line reveals an increased expression of known cancer-
related genes (e.g., GJA1, CD44, IGFBP6) that are downregulated in prostate cancer. Similarly, cancer genes whose
expression is decreased in the 4-2 cell line were upregulated in prostate cancer (e.g., MUC1, IL6). The direct role
of PACE4 in prostate cancer is most likely through the upregulated processing of growth factors or through the aber-
rant processing of growth factors leading to sustained cancer progression, suggesting that PACE4 holds a central
role in prostate cancer.
Translational Oncology (2011) 4, 157–172
Address all correspondence to: Dr. Robert Day, Institut de Pharmacologie de Sherbrooke, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, 3001 12e Ave.
Nord, Sherbrooke, Québec, Canada J1H 5N4. E-mail: robert.day@usherbrooke.ca
1This work was funded by grants from the Canadian Institutes of Health Research, the Ministère du Développement Économique de l’Innovation et de l’Exportation (to R.D.),
the Centre National de la Recherche Scientifique (to M.S. and I.F.), and the Agence Nationale de la Recherche (to I.F.) and scholarships from Natural Sciences and Engineering
Research Council of Canada (to F.D. and S.R.) and from Fonds de la Recherche en Santé du Québec (to F.D.). R.D. is a member of the Centre de Recherche Clinique Etienne-
Le Bel (Sherbrooke, Québec, Canada).
2This article refers to supplementary materials, which are designated by Tables W1 and W2 and are available online at www.transonc.com.
3Present address: Laboratoire de Microbiologie, Institut de Recherche Pierre Fabre, Toulouse, France.
Received 17 December 2010; Revised 2 February 2011; Accepted 14 February 2011
Copyright © 2011 Neoplasia Press, Inc. 1944-7124/11
DOI 10.1593/tlo.10295
www.transonc.com
Trans la t iona l Onco logy Volume 4 Number 3 June 2011 pp. 157–172 157
Open access under CC BY-NC-ND license.
Introduction
Cancer cells are characterized by multiple genetic alterations that
confer physiological changes, leading to uncontrolled division and
ability to invade other tissues [1]. These acquired capabilities, namely
cell proliferation, tissue invasion, and adhesion, are essential for ma-
lignant growth and progression. Numerous studies have associated
the family of enzymes known as the proprotein convertases (PCs)
to cancer [2–8]. PCs are serine proteases that cleave substrates at
R-X-K/R-R↓ motif [9,10]. These processing events, resulting in
the activation of protein precursors, occur at multiple levels of cell
secretory pathways, and even at the cell surface. In mammalian cells,
seven basic amino acid cleaving members of this family have been
identified: furin, PACE4, PC1/3, PC2, PC4, PC5/6, and PC7. PCs
show differential expression levels within tissues, ranging from ubiq-
uitous (e.g., furin) to an endocrine-restricted expression (e.g., PC1/3
and PC2).
The first association of PCs with cancer was done by comparative
studies of normal and cancerous cells showing higher expression of
PCs in small cell lung cancer [11], non–small cell lung carcinoma
[12], breast [13], colon [14], and head and neck [15] tumor cells
or lower expression in ovarian cancer [16]. A correlation between ex-
pression of some PCs, namely furin and PACE4, and tumor cells’ ag-
gressiveness has been established for different cell types [8,15,17–20].
Thus, it is hypothesized that through processing events, cancer cells
have a higher capacity (i) to remodel the extracellular matrix (e.g.,
MT1-MMP and MT2-MMP; [17,21,22]), (ii) to interact with their
host microenvironment to favor adhesion (e.g., IL-1α, TNF-α, and
E-selectin [7]); and (iii) to modulate their proliferation and differen-
tiation (e.g., IGF-1 receptor [7], VEGF-C, -D [23,24], PDGF-A, -B
[24,25], TGF-β [26]). One possible mechanism whereby PCs are
critical in cancer progression could be on the basis of differential pre-
cursors processing by overexpressed PCs. Alternatively, PCs over-
expression is required to sustain pathophysiological functions to
maintain cancer cells immortality, for example to sustain the processing
of required growth factors or proangiogenic factors. Together, these
studies suggest that PCs processing events are directly linked to tumor
development by allowing cancer cells to maintain some of their ac-
quired capabilities.
Because the PC family of enzymes is very large and often respon-
sible for redundant processing functions, more precise studies are
required if we are to understand their specific roles in different can-
cer types. Thus, there is a need for potent, specific, and cell-effective
inhibitors, either pharmacologic or molecular, for each member of
this enzyme family. Pharmacological tools are limited as many lack
the required specificity for single PCs [9,27–30]. For example, a
study by Uchida et al. [31] showed that treatment of prostate cancer
cell lines with the general PC inhibitor decanoyl-Arg-Val-Lys-Arg-
chloromethylketone (dec-RVKR-CMK) inhibited prostate-derived
factor processing and resulted in the loss of luminal cell phenotype
and induction of basal cell phenotype as demonstrated by alterna-
tions in the expression of cytokeratins 8, 14, 18, and 19, markers
of prostate epithelial cell differentiation. Because dec-RVKR-CMK
inhibits all PCs, the study could not distinguish which PCs expressed
in the prostate cancer cell lines were more important. To ask the ques-
tion as to which PCs are the most important for cancer progression,
molecular approaches targeting specific PC messenger RNA (mRNA)
are closer to achieving this goal. There are various sequence-specific ap-
proaches taking advantage of either endogenous ribonucleases (e.g.,
small interfering RNA [siRNA] and phosphorothioate antisense oligo-
nucleotide) or their intrinsic catalytic activity (e.g., deoxyribozyme and
ribozyme) to drive the degradation of the targeted RNA [32].
In the present study we chose to examine the role of PCs in pros-
tate cancer. In men, prostate cancer accounts for the highest incident
cases and the second most deadliest cancer type [33]. Because disease
diagnosis and treatment have been little changed in the past 30 years,
it is possible that a better understanding of the molecular events lead-
ing to advanced prostate cancer states could lead to the development
of new, efficient, and targeted therapies [34]. We first evaluated the
implication of each PC on different types of prostate cancer biopsies
and detected the unique PACE4 mRNA overexpression. Based on
these findings, we created a DU145 cell line model, using the switch
on/off adapter-hepatitis delta virus ribozyme (SOFA-HDVRz) as a
RNA silencing tool, to investigate PACE4’s contribution in androgen-
independent prostate cancer cells. The results of this study, based on
in vitro assays, gene expression, and proteomic profiling, as well as
animal studies, led us to the conclusion that PACE4 plays a critical
role in the progression of prostate cancer and therefore could be a novel
therapeutic target for its treatment.
Materials and Methods
Patients and Samples
Prostate tumor samples were obtained from either St Louis and
Bichat Hospital (Paris, France) or Tournan’s clinic (Tournan en Brie,
France), as previously described [35]. Each patient included has signed
the sample informed consent form. Sample tissues from the 34 pa-
tients with clinically localized prostate tumors were obtained by
removing clinically localized tumors by radical prostatectomy and clas-
sified according to their clinical stage using the TNM system [36,37].
After pathological examination, 18 samples were at stage pT2, whereas
16 samples were at stage pT3. The sample tissues from hormone-
refractory recurrent prostate carcinoma were obtained from patients
with metastatic disease at diagnosis. Because these patients were not
amenable to radical surgery, they received endocrine therapy, either by
classic androgen deprivation (orchidectomy or luteinizing hormone–
releasing hormone agonist administration) or by maximal androgen
blockade (castration combined with antiandrogen therapy). These
patients relapsed, and their tumors became clinically androgen-
independent. The 13 samples of these hormone-refractory recurrent
prostate carcinomas were obtained during transurethral resection.
Suspect areas were examined histopathologically in the surgery suite,
and thick shave sections were taken for research purposes. These pre-
selected tumor specimen sections were then sliced on each side in the
laboratory and again subjected to pathological examination. Confirmed
areas were carefully microdissected using a scalpel and the assistance of
an experienced pathologist. Well-characterized matched normal pros-
tate specimens (nine samples) from the 34 patients with clinically
localized prostate tumors who underwent radical prostatectomy were
used to assess basal target gene mRNA expression. Normal-looking
areas of each surgical specimens were examined histologically for the
absence of cancer cells and selected on their microscopic pathological
criteria to avoid the inclusion of areas with benign hyperplasia.
Normal specimens were then proceeded as previously described for
tumor tissues.
Real-time Polymerase Chain Reaction on Tissues
The RNA was extracted from dissected tissues with an acid-phenol
guanidium method, reverse-transcribed, and submitted to quantitative
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polymerase chain reaction (PCR) as previously described [35]. A
genomic DNA and nontemplate control were included in each exper-
iment. Samples and controls were tested in duplicate. The threshold
cycle (C t ) numbers obtained from PCR amplifications were expressed
as fold change in target gene expression (PACE4) relative to an en-
dogenous control gene (PPIA; peptidyl prolyl isomerase A gene en-
coding cyclophilin A). The primer sequences for endogenous control
gene PPIA (the peptidyl prolyl isomerase A gene encoding cyclo-
philin A) were described earlier [35]. The primer sequences were as
follows: PACE4 sense, 5′-CAAGAGACCCAGGAGCATCCC-3′;
PACE4 antisense, 5′-ACCCGCTGGTCCGAGTGCT-3′; furin sense,
5′-CCAGGATGAATCCCAGGTGCTC-3′; furin antisense,
5′-GGAGGGTGAAGAGTGCCGACC-3′; PC7 sense, 5′-CATCCAG-
GACATTGCACCCAAC-3′; and PC7 antisense, 5′-GGTTGCCAT-
TCTCCACATCCG-3′.
In Situ Hydridization
The in situ hydridization protocol using digoxigenin-labeled comple-
mentary RNA probes have been described in details previously [38].
SOFA-HDVRz Design, Cloning, and In Vitro Cleavage Assays
Bioinformatic analysis. Human PACE4 complementary DNA
(cDNA) sequence (M80482) was used for the determination of
the optimal SOFA-HDVRz targeting site. The selection criteria were
(i) the first nucleotide (nt) should be a G to form the required wob-
ble bp within the P1 stem; (ii) after the 6 subsequent nt of the P1
stem, a 5 nt spacer was added; and (iii) a 12-nt biosensor stem was
used to complete the design. Thus, the targeted site on cDNA was 5′
(GN6)P1-(N5)Spacer-(N12)Biosensor-3′ (Figure 2A). We focused our
search for optimal cleavage site within the first 1200 nt of the PACE4
cDNA and tested several potential targeting sites with the Ribosub-
strates online software (http://www.riboclub.org/ribosubstrates) [39].
This integrated software searches in selected cDNA databases all
potential substrates for a given SOFA-HDVRz. These potential sub-
strates include mRNA with perfect matches with the catalytic RNA
tested, but also the wobble bp and mismatches. Only SOFA-HDVRz
with a human PACE4-specific biosensor and harboring a minimum
of wobble bp were considered.
Plasmid DNA constructs. As previously detailed [40], we used the
expression vector ptRNAVal/hygromycin containing the RNA poly-
merase III promoter tRNAVal promoter for cellular applications. A
PCR strategy was used to create a DNA template containing a 5′-KpnI
restriction site and a 3′-blunt end. The sequences of the two comple-
mentary and overlapping DNA oligodeoxynucleotides used were as
follows: sense, 5′-ATCCATCGGGTACCGGGCCAGCTAGTTT
(GGCCTCTGCTAC)BS(CAAC)BLCAGGGTCCACC-3′ and, anti-
sense, 5′-CCAGCTAGAAAGGGTCCCTTAGCCATCCGCGAA-
CGGATGCCCA(ATCAAC)P1ACCGCGAGGAGGTGGACCCTG
(GTTG)BL-3′. The underlined nt correspond to the KpnI restriction
site, and those in parenthesis to the PACE4 specific biosensor (BS),
blocker (BL) and P1 stem (P1) of the PACE4-SOFA-HDVRz. The
purified and KpnI-digested PCR product was cloned in the expression
vector previously digested with KpnI and EcoRV restriction enzymes.
The vector used to restore PACE4 mRNA expression level contained
the full-length PACE4 cDNA and a neomycin resistance gene (kindly
provided by Dr J.W. Creemers [41]).
RNA synthesis. As previously described, radiolabeled PACE4 RNA
was obtained from transcription of an XhoI-digested pcDNA3 vector
containing a chimeric cDNA composed of the PC5/6A signal pep-
tide linked to proPACE4 coding sequence [41] using T7 RNA poly-
merase with 50 μCi of [α-32P]GTP [40]. The catalytic RNA were
synthesized using a PCR-based strategy with the expression vectors
to generate DNA templates containing a 5′-T7 RNA polymerase
promoter using either the following sense primer 5′-TTAATAC-
GACTCACTATAGGGACCGTTGGTTTCCGTAG-3′ or 5′-
TTAATACGACTCACTATAGGGCCAGCTAGTTT-3′, comple-
mentary to the tRNAVal promoter or the PACE4-SOFA-HDVRz,
respectively (the underlined nucleotides correspond to the T7 RNA
polymerase promoter sequence). The antisense oligodeoxynucleotide
sequence used for both PCR was 5′-CCAGCTAGAAAGGGTCCC-
TTA-3′. After PCR, the purified products were used as templates for
T7 RNA polymerase transcription of tRNAVal-PACE4-SOFA-HDVRz
or PACE4-SOFA-HDVRz, as described previously [40]. All products
were purified on denaturing 5% (PACE4 transcript) or 7.5% (for
PACE4-SOFA-HDVRz transcripts) PAGE.
Cleavage assay. The SOFA-HDVRz cleavage assays under single
turnover conditions ([SOFA-HDVRz] > [PACE4 RNA]) were done
at 37°C for 3 hours in a 10-μl reaction containing trace amount of radio-
labeled PACE4 RNA and 1 μM of SOFA-HDVRz in reaction buffer
containing 50 mM Tris-HCl, pH 7.5, and 10 mM MgCl2. The reac-
tions were stopped by the addition of loading buffer (97% formamide,
1 mM EDTA [pH 8.0], 0.025% xylene cyanol and 0.025% bromo-
phenol blue), electrophoresed on denaturing 5% PAGE gel, and ana-
lyzed with a PhosphorImager (Amersham Biosciences, Sunnyvale, CA).
Cell Culture and DNA Transfection
Human cancer prostate cell lines DU145 were obtained from
ATCC (Manassas, VA). Cells were maintained in Roswell Park Me-
morial Institute medium (RPMI 1640) supplemented with 5% fetal
bovine serum (Wisent Bioproducts, St-Jean-Baptiste,Quebec, Canada).
Cells were grown at 37°C in a water-saturated atmosphere in air/CO2
(5%). Cells were transfected using Lipofectamine 2000 (Invitrogen,
Burlington, Ontario, Canada) as per manufacturer’s instruction and
were selected for resistance to hygromycin B (Invitrogen) at 125 μg/ml,
with 200 μg/ml of neomycin for double-transfected cells. The stable
cell line transfected with the SOFA-HDVRz expression vector was
named 4-2, whereas the 4-2 cell line stably transfected with the PACE4
expression vector was named 4-2 + PACE4.
Northern Blot Hybridizations
RNA extractions and Northern blots were performed as previously
described [40]. The 1066-bp cDNA for human furin probe was ob-
tained by digestion of the full-length clone with XhoI enzyme [42]. A
456-bp cDNA fragment of PACE4 was cloned in pGEM-T easy vec-
tor system (Promega, Madison, WI) by reverse transcription–PCR
on DU145 total RNA with specific primers [13]. This vector was
subsequently used for probe transcription. For the PC7 probe, we
used a 285-bp rat cDNA [43], and for bovine 18S ribosomal RNA
probe, a 600-bp cDNA [44] was used. The ImageJ software 1.37v
(http://rsb.info.nih.gov/ij/) was used for all densitometric analyses.
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Microarray Analysis
Sample preparation. RNA from DU145 or 4-2 cell pellets (in du-
plicate) was extracted using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions and purified using RNeasy mini kit
(Qiagen, Mississauga, Ontario, Canada). The quality of the RNA was
assessed using a 2100 Bioanalyzer with the RNA 6000 Nano LabChip
kit (Agilent Technologies, Mississauga, Ontario, Canada).
Data processing. The microarray hybridization and the data collec-
tion were performed on the Functional Genomics Platform of the
McGill University and Genome Québec Innovation Centre (Montréal,
Quebec, Canada) using Illumina whole genome Human WG-6 v3.0
bead chip (38,275 genes). The processing of data was done with the
software FlexArray v1.2 (http://genomequebec.mcgill.ca/FlexArray/).
Briefly, the raw data were preprocessed and normalized for each array
using the “lumi” algorithm. Then, the mean fold changes of normal-
ized data were calculated for DU145 versus 4-2. Statistical analysis was
performed using the Significance Analysis of Microarrays method,
which uses a modified t test statistic and sample-label permutations
to evaluate statistical significance [45].
Real-time PCR validation. The real-time PCR assays were carried
out on the Mx3000P quantitative PCR system using the Brilliant II
SYBR Green kits (Stratagene, Cedar Creek, TX). Briefly, the RNA was
DNase I–treated (Invitrogen), reverse-transcribed using Superscript II re-
verse transcriptase (Invitrogen), and RNaseH-treated (Ambion, Austin,
TX) before quantitative PCR. The reaction mixtures combined 1 μg of
cDNA with 12.5 μl of 2× master mix containing primers at a 300-nM
final concentration. The PCR profile was one cycle for 10 minutes at
95°C, 40 cycles of 30 seconds at 95°C, 1 minute at 60°C, and 30 sec-
onds at 72°C. Primers were designed using Beacon Designer software
(http://www.premierbiosoft.com). The sequences of primers used were
as follows: SERPINE2 (NM_006216), sense 5′-CCCACTTCAATCCT-
CTGTCTCTC-3′ and antisense 5′-CCCAGGACCGACGCAATC-3′;
CDK6 (NM_001259), sense 5′-GCCGCCCAGCCAGAACAC-3′ and
antisense 5′-CTCCAGATAGCAATCCTCCACAGC-3′; IGFBP6
(NM_002178), sense5′-GCGTGGAGGAGGAGGATGG-3′andanti-
sense 5′-CTTGGGCGGATGGCACTG-3′; TGFBI (NM_000358),
sense 5′-GTGCGGCTGCTGGCTCTC-3′ and antisense 5′-GCT-
GGTAGGGCGACTTGGC-3′; CCNA1 (NM_003914), sense 5′-
YGAAGAAGCAGCCAGACATC-3′ and antisense 5′-AAGTTGA-
CAGCCAGATACAGG-3′; IGFBP3 (NM_001013398), sense 5′-
TTCTGCTGGTGTGTGGATAAG-3′ and antisense 5′-GGCGTC-
TACTTGCTCTGC-3′; THBS1 (NM_003246), sense 5′-GGACT-
CGCTGTAGGTTATGATG-3′ and antisense 5′-CGGCTG-
CTGGACTGGTAG-3′; MUC1 (NM_002456), sense 5′-CTGGT-
GCTGGTCTGTGTTC-3′ and antisense 5′-GCTGCCCGTAG-
TTCTTTCG-3′; and ACTB (NM_007393), sense 5′-GGGAAATC-
GTGCGTGACATCAAAG-3′ and antisense 5′-CATACCCAAGAA-
GGAAGGCTGGAA-3′. For all PCRs, standard curves, dissociation
curves, and migration of PCR products on acrylamide gels were done
to confirm the specificity of the products. Moreover, two PCRs were
performed as negative controls: one without cDNA template, and
the other using reverse transcription reaction that never received
SuperScript II reverse transcriptase enzyme. Results were estimated
as C t values, and the fold change of the expression of target gene in
DU145 compared with 4-2 cells was expressed as 2ΔΔC t. The ΔC t
was obtained from the subtraction of the mean C t for the target with
the mean C t for the internal control gene (β-actin). The ΔΔC t is the
mean difference between the ΔC t obtained from DU145 RNA ex-
tracts minus ΔC t obtained from 4-2 RNA extracts. All PCRs were
repeated twice for each set of primers.
Conditioned Growth Medium Preparation
Four 10-cm plates were seeded with 1.0 × 106 cells (DU145 or 4-
2 cells) in complete growth media. The next day, the cells were
washed twice with PBS, and the growth medium was replaced with
5 ml of serum-free RPMI for 1 hour. The conditioned media were
collected, filtered through 0.45-μm Acrodisc syringe filter units (Pall
Corporation, Ville St. Laurent, Quebec, Canada), and kept on ice.
The filtrates were concentrated to a final volume of 350 μl with
Amicon Ultra centrifugal filter devices with a 3-kDa molecular
weight cutoff (Millipore, Bedford, MA). Fresh RPMI was treated
the same way as a control for cell experiments.
MTT Proliferation Assay
The cell proliferation was measured by the colorimetric MTT
assay (thiazolyl blue tetrazolium bromide; Sigma-Aldrich, Oakville,
Ontario, Canada). Briefly, cells were seeded in 96-well plates (BD Bio-
sciences, Mississauga, Ontario, Canada) in triplicate with 100 μl of a
5.0 × 104-cells/ml cell suspension in complete growth medium. The
following day, cells were carefully washed twice with PBS twice and
were incubated with 50 μl of either fresh RPMI, concentrated RPMI,
DU145 or 4-2 concentrated conditioned growth media (DU145 and
4-2 CM, respectively). After 48 hours, 12.5 μl of an MTT solution
(5 mg/ml in PBS) was added to each well for 4.5 hours at 37°C/
5% CO2. The medium was then carefully discarded, and the cells were
solubilized with 100 μl of isopropanol/0.04N HCl solution. The ab-
sorbance was measured at a wavelength of 550 nm with a reference at
650 nm in microplate reader (SpectraMax190; Molecular Devices,
Sunnyvale, CA).
Cell Count Assay
Cells were plated at a density of 5.0 × 104/well in six-well plates
(BD Biosciences) in duplicates. Complete growth medium was
changed after 48 hours. After incubation, cells were washed in PBS,
trypsinized, and counted after staining in 0.4% (wt/vol) trypan blue
solution (Sigma-Aldrich). Only viable cells were counted in duplicate.
Colony Formation Assay
Cell lines were seeded in six-well plates (BD Biosciences) at a den-
sity of 300 cells/well in triplicate. Cells were maintained in complete
growth medium for 10 days. After colony formation, medium was
discarded, and cells were washed once with PBS. Colonies were fixed
and stained in 5 mg/ml methylene blue/50% methanol solution for
10 minutes. Excess of staining solution was removed carefully with
distilled water and the plates were dried overnight before scanning
with Li-Cor Odyssey Infrared Imaging System (Li-Cor Biosciences,
Lincoln, NE). Scanned images were analyzed with ImageJ software
1.37v (http://rsb.info.nih.gov/ij/) to measure the total particle area.
Flow Cytometric Analysis of Apoptosis without Cell Fixation
Propidium iodide DNA staining. Cell lines were seeded in 10-cm
plates (5.0 × 105 cells) in complete growth media and grown over-
night. Afterwards, cells were washed three times with PBS, incubated
in fresh complete growth medium for 12 hours, and harvested with
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trypsin (including the supernatant). The cell pellets were washed
once with PBS, centrifuged, and resuspended in 50 μl of PBS. A
chromatin decondensation treatment was performed using 450 μl
of H-buffer/Triton X-100 (20 mM HEPES, pH 7.2, 0.16 M NaCl,
1 mM EGTA, and 0.05% Triton X-100) warmed at 37°C for 1 min-
ute on ice. After this incubation, cells were gently centrifuged for
5 minutes and 450 μl of the supernatant was discarded. Cell pellets
were then gently resuspended with the remaining supernatant, and
the DNA staining was performed using 450 μl of H buffer con-
taining 10 μg/ml of RNAseA (Sigma-Aldrich) and 10 μg/ml of
propidium iodide (PI) (Sigma-Aldrich) for 30 minutes at room tem-
perature in the dark.
Fluorescence-activated cell sorter analysis. After the PI staining,
cells were analyzed on a FACScan cytometer (BD Biosciences). For-
ward and side scatter signals were used to establish the live gate to
exclude debris and cell clumps. A minimum of 10,000 gated events
by sample were acquired. The fluorescence of PI was collected in red
channel on a linear scale (FL3). A second live gate was set using the
FL3-A and FL3-W parameters of the doublet discrimination module,
allowing single cell measurements. Fluorescence intensity distribu-
tion was analyzed with the CellQuest software (BD Biosciences),
whereas the distribution of nonapoptotic cells into the phases of
the cell cycle was determined using the ModFit software (Verify Soft-
ware House, Topsham, ME).
Human Tumor Xenograft Models
Four-week-old female athymic nude mice (nu/nu; Charles River
Laboratories, Wilmington, MA) were inoculated subcutaneously at
the opposite sides of the flank with 3.0 × 106 cells per inoculum (five
mice/group). Cells were grown in complete media and harvested at
their exponential growing state. Mice were housed under pathogen-
free conditions, and the implantations were done under anesthesia
conditions in laminar flow hood. Xenografts were measured three
times per week, and volume (V ) was determined by this equation:
V = (L × W 2) × 0.5, where L is the length and W is the width of
the xenograft.
Immunohistochemistry
Subcutaneous tumors derived from DU145 and 4-2 cell lines were
eradicated, formalin-fixed, and paraffin-embedded. Immunohisto-
chemical staining was carried out on 3-μm sections by the Ventana
NexES autostainer with the enzyme-labeled biotin-streptavidin system
and the solvent-resistant DAB Map detection kit (Ventana Medical
System, Tucson, AZ) using either p53 (1:200), MUC1 (epithelial
membrane antigen; 1:200) or CDK4 (cyclin-dependent kinase 4;
1:100) anti–human monoclonal antibodies or prostate-specific antigen
(PSA; 1:10,000) anti–human polyclonal antibody (Dako Canada,
Burlington, Ontario, Canada; Thermo Fisher Scientific, Fremont,
CA). The slides were counterstained with hematoxylin. The images
were acquired using an Axioskop 2 phase-contrast microscope (Carl
Zeiss, Thornwood, NY) and processed using Image Pro software
(Media Cybernetics, Bethesda, MD).
Mass Spectrometry Analysis of Conditioned Media
Sample preparation. The DU145 and 4-2 conditioned growth
media were prepared as described earlier in this section, except that
the concentrated media were washed in centrifugal filter device with
12 ml of water before being collected and lyophilized. The samples
were then solubilized with 100 μl of acidified water–0.1% trifluoro-
acetic acid. Acetone precipitation was performed with a ratio 4:1
(vol/vol). After a centrifugation at 13,000 rpm at 4°C for 30 minutes,
pellets were solubilized in 50 mM pH 8.0 ammonium bicarbonate
(NH4HCO3), a reduction of cysteine residues with a 45-mM dithio-
threitol solution was performed for 15 minutes at 50°C, and a sub-
sequent alkylation was performed with a 100-mM iodoacetamide
solution for 15 minutes at room temperature in the dark.
Trypsin digestion. The samples were placed on ice for 30 minutes in
50 μl of proteases solution (sequence grade-modified trypsin [Promega]
at 0.02 mg/ml in 25 mM NH4HCO3). Digestions were performed
overnight at 37°C. The samples were then desalted and concentrated
using C18 ZipTips (Millipore) before mass spectrometry analyses.
Matrix-assisted laser desorption/ionization tandem time-of-flight
(MALDI-TOF/TOF) analyses. The MALDI TOF/TOF mass
spectrometer (Ultraflex II; Bruker Daltonik, Bremen, Germany) used
in this study was equipped with an Nd:YAG laser (355 nm) with a
repetition rate of 200 Hz. Mass spectra were the sums of 8000 shots
acquired in positive ion reflectron TOF mode. The acceleration poten-
tial was 25 kV. For MS2 analysis, 2000 shots were acquired for parent
ion selection and 10,000 shots for fragments selection. For MALDI
analysis, the matrix used was α-cyano-4-hydroxycinnamic acid ACN:
H2O/trifluoroacetic acid 0.1% (7:3). Calibration was performed with
peptides calibration standard (Bruker Daltonik). Samples underwent
software processing with FlexAnalysis 2.4 and Biotools 2.2 (Bruker
Daltonik) for baseline subtraction and peaks detection.
Protein identification. Protein identification was performed under
the MASCOT sequence query search program using the SwissProt
database filtered for the taxonomy Homo sapiens. A tolerance of 1 Da
for peptide and 0.6 Da for tandem mass spectrometry (MS/MS) was
set. Only protein sequences with a MOWSE score higher than 36 (in-
dicating significant homology or identity) and identified in several sam-
ples representing at least two significant MS/MS were considered.
Methionine oxidation and acetylation of N-terminals were defined as
variable modification.
Statistical Analyses
All experiments were repeated at least three times, except for hu-
man tumor xenografts and microarray analysis. Comparisons be-
tween the test group and controls of this study were done using
Student’s t test.
Results
PACE4 Expression in Clinically Localized Prostate Tumors
We tested the expression of PCs in 47 primary prostate tumor
samples obtained from patients undergoing surgery. The majority
of the patients (i.e., n = 34) had clinically localized tumors and 13
had hormone-refractory recurrent prostate carcinoma. All collected
samples were subjected to histopathologic examination. Only tissues
where all epithelial cells were neoplastic were dissected and used for
further studies. Real-time PCR was used to evaluate PACE4, furin,
and PC7 mRNA expression levels in prostate tumor tissues using nine
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matched normal prostate tissues as a reference (Figure 1A). The tis-
sues were grouped into similar clinical stages based on TNM system
as 18 pT2 samples (tumors strictly confined to the organ), 16 pT3
samples (tumors with extracapsular extension), and 13 hormone-
refractory samples (tumors no longer responsive to endocrine therapy).
The mean relative PACE4 mRNA expression levels (Figure 1A) were
significantly higher for all cancer groups (pT2, 4.0 ± 0.1; pT3, 4.3 ±
0.2; and hormone refractory, 2.8 ± 0.1), when compared with the
mean level found in normal prostate tissues (1.8 ± 0.1). Real-time
PCR for the other PCs showed that furin, PACE4, and PC7 were
the most expressed PCs in normal prostate tissues. However, only
PACE4 mRNA expression increased in tumor tissues, whereas the
others showed a generalized reduction in cancer tissues. This higher
PACE4 expression, particularly in epithelial cells, was directly assessed
Figure 1. Relative mRNA expression levels of PCs in normal and tumoral prostate tissues. (A) Real-time PCRs from tissue specimens
were performed with PACE4, furin, PC7, and PPIA specific primers. Nine normal prostate tissues and 47 prostate tumors (separated into
three groups) were used for the comparative analyses. Clinical stage classification of prostate tumors, based on TNM system, was as
follows: pT2, tumors strictly confined to the organ (18 samples); and pT3, tumors with extracapsular extensions (16 samples). Hormone-
refractory prostate tumor tissues (13 samples) were issued from patients who relapsed after receiving endocrine therapy. Values are
mean ± SEM. *P < .05, **P < .001. (B) PACE4 in situ hybridization in epithelial cells from normal and tumoral prostate tissues (arrows
indicate purple staining corresponding to PACE4 mRNA).
Table 1. PACE4 Is Upregulated in Prostate Cancer according to Oncomine Database*.
Study Description Fold Change P Number of
Measured Genes
Overexpression
Gene Rank
Reference
1 Prostate carcinoma (n = 8) vs
prostate gland (n = 4)
1.951 1.58e − 4 4564 7 (in top 1%) Cancer Res. 2001;61(15):5692–5696
2 Prostate carcinoma (n = 61) vs
prostate gland (n = 39)
2.190 9.12e − 15 10,021 35 (in top 1%) Proc Natl Acad Sci USA. 2004;101(3):811–816
3 Prostate carcinoma (n = 65) vs
prostate gland (n = 23)
1.246 4.65e − 7 7820 89 (in top 2%) J Clin Oncol. 2004;22(14):2790–2799
4 Prostate carcinoma (n = 44) vs
prostate gland (n = 13)
1.271 7.56e − 5 12,427 113 (in top 1%) Cancer Res. 2006;66(8):4011–4019
5 Prostate carcinoma (n = 7) vs
prostate gland (n = 6)
2.627 5.93e − 4 19,079 250 (in top 2%) Cancer Cell. 2005;8(5):393–406
6 Prostate adenocarcinoma (n = 27) vs
prostate gland (n = 8)
1.349 5.30e − 4 17,358 1202 (in top 7%) Cancer Res. 2003;63(14):3877–3882
*Available at: http://www.oncomine.org.
162 PACE4 in Prostate Cancer D'Anjou et al. Translational Oncology Vol. 4, No. 3, 2011
Figure 2. Down-regulation of PACE4 expression in DU145 cells. (A) The secondary structure of both the “OFF” and “ON” conformation
of the SOFA module (box) attached to the classic HDVRz. The biosensor (in red, BS) and the blocker (in green, BL) can be modified to be
hybridized on a specific mRNA target (N indicates A, C, G, or U). After the recognition of the mRNA, the P1 stem (in purple, P1) issued
from the sequence-specific hybridization of the HDVRz with the targeted RNA will allow the catalytic cleavage of the latter, as indicated
by the arrow. (B) Autoradiogram of in vitro cleavage assays performed with either the SOFA-HDVRz or the chimeric RNA transcript
tRNAVal-SOFA-HDVRz both specific for PACE4 RNA. The control lane is the migration of the internally 32P-radiolabeled 3800 nt PACE4
RNA alone. The BS, BL, and P1 nucleotide sequences of the PACE4-SOFA-HDVRz used are indicated in the Materials and Methods
section. XC indicates the position of xylene cyanol after migration on the denaturing 5% PAGE gel. (C and D) Autoradiograms of North-
ern blot hybridizations showing levels of PACE4 (C), furin (D), and PC7 (D) mRNA in untransfected DU145 cells (control cell line) or in cell
lines either transfected with the expression vector coding for the tRNAVal-PACE4-SOFA-HDVRz alone (4-2) or cotransfected with a
PACE4 cDNA expression vector (4-2 + PACE4) are shown. The bands corresponding to the 18S ribosomal RNA are shown for all blots.
The size markers are shown on the right. The expression levels of PACE4 mRNA in transfected cell lines relative to the unstransfected
DU145 cells were obtained by densitometric analyses using 18S ribosomal RNA as loading control (C). Values are mean ± SEM (n = 3).
*P < .05.
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by an in situ hydridization. Normal prostate tissues showed the
expected epithelial cell distribution of PACE4 mRNA. However, tu-
mors showed disorganization of the tissue structure, with a higher
PACE4 expression and even cells invading the stroma (Figure 1B).
Because PACE4 was the only member of the PC family to be
overexpressed in prostate tissues, we investigated its expression levels
in the Oncomine database (http://www.oncomine.org). As summa-
rized in the Table 1, six independent studies reported a significant
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overexpression of PACE4 (P < .001) in prostate cancer tissues com-
pared with corresponding normal tissues. Moreover, in five of the six
studies, the PACE4 overexpression rank was within the top 2%,
whereas the remaining was in the top 7%. It is noteworthy to report
that furin, PC5/6, and PC7 did not show an up-regulation of their
expression within those studies. These microarray studies, combined
with our real-time PCR results, strongly suggest that PACE4 is asso-
ciated with prostate cancer (i.e., potential biomarker or therapeutic
target). Although these studies only measured PCs mRNA expression
levels in prostate cancer tissues and not their enzymatic activity, we
still decided to focus on PACE4 for this study.
Rational Design of SOFA-HDVRz Targeting PACE4 mRNA
SOFA-HDVRz as a gene silencing tool. Considering the high
expression level of PACE4 mRNA in tumoral prostate tissues, we
decided to evaluate the contribution of this enzyme to the mainte-
nance of the tumorigenic state in vitro and in vivo. Because there are
no PACE4-specific and potent inhibitors available [9,46], we opted
for a highly specific molecular approach targeting PACE4 mRNA.
We previously showed that hepatitis delta virus ribozyme (HDVRz)
could be a powerful and specific silencing tool in cultured cells [40].
Here, we tested a new generation of HDVRz harboring a switch on/
off adapter (SOFA-HDVRz), resulting in an enhanced in vitro spec-
ificity and potency [47,48]. As shown in Figure 2A, the SOFA-
HDVRz has three new features over the classic HDVRz. First, a
blocker stem of 4 nt prevents the formation of the P1 stem, essential
for the cleavage event. A biosensor of 12 nt at the 5′ end of the
blocker stem compels the SOFA-HDVRz to maintain an inactive
state (“OFF” conformation) until the right complementary RNA hy-
bridizes. This sequence-specific hybridization releases the P1 stem
from the blocker, allowing the formation of the P1 stem.
SOFA-HDVRz design. We used the complete sequence of human
PACE4 cDNA (GenBank database accession number M80482) to
design a selective SOFA-HDVRz against PACE4 mRNA. The bio-
informatics analysis of the selected sequence reveals no other matches
in the entire genome than that of PACE4. The exquisite specificity of
the SOFA ribozyme approach has been validated [49]. Figure 2B
shows the in vitro cleavage of PACE RNA with a selected PACE4-
SOFA-HDVRz cleaving into the prodomain coding sequence of the
transcript at position 519. As shown on the autoradiogram of the
PAGE gel, the reaction generated only one cleavage product that
could be seen after the addition of the PACE4-SOFA-HDVRz. To
confirm the specificity of this molecule, we firstly tested the same
ribozyme against a radiolabeled human furin transcript, and secondly,
we used a catalytically inactive mutant (C76A) of the SOFA-PACE4-
HDVRz against the PACE4 transcript [47]. In both cases, no cleavage
product could be observed, confirming the capacity of the PACE4-
SOFA-HDVRz to selectively cleave its target in vitro.
Down-regulation of PACE4 mRNA in DU145 Cells
Expression vector. We used an expression vector containing the
tRNAVal promoter to produce the PACE4-SOFA-HDVRz into trans-
fected cells [40]. To insure that the tRNAVal part did not interfere with
the catalytic activity of the associated SOFA-HDVRz, we performed an
in vitro cleavage assay by incubating the chimeric transcript (tRNAVal-
SOFA-HDVRz) with an internally radiolabeled PACE4 RNA (Fig-
ure 2B). As seen on the autoradiogram of the PAGE gel, the addition
of the tRNAVal motif did not modify neither the specificity nor the
level of the cleavage activity of the PACE4-SOFA-HDVRz.
Northern blots. We transfected the PACE4-SOFA-HDVRz expres-
sion vector (named ptRNAVal-PACE4-SOFA-HDVRz) into DU145,
a highly invasive, androgen-independent prostate epithelial tumor
cell line. These cells were chosen for their high level of PACE4 ex-
pression, aggressiveness, and ease of transfection when compared with
the androgen-dependent LNCaP or the androgen-independent PC-3
cells. Stable cell lines transfected were established by the selection of
clones resistant to hygromycin B. Northern blot analyses on total RNA
extracts were performed for wild-type DU145 (DU145), DU145
transfected with ptRNAVal-PACE4-SOFA-HDVRz (cell line 4-2), and
4-2 + PACE4 cells, which are 4-2 cell lines cotransfected with the
PACE4 cDNA expression vector. As seen in Figure 2C , the PACE4
mRNA expression level in the SOFA-HDVRz transfected cell line
was significantly reduced when compared with the untransfected cells.
These levels were partially reestablished by the overexpression of
PACE4 cDNA. The graph shows a densitometric analysis using 18S ri-
bosomal RNA as loading control performed to quantify the mRNA
expression levels in these clonal cell lines using wild type DU145 cells
as reference (0.3 ± 0.1 and 0.75 ± 0.06 for 4-2 and 4-2 + PACE4, re-
spectively). The mRNA expression levels of two other endogenous
PCs confirmed the specificity of the PACE4-SOFA-HDVRz cleav-
age. Levels of furin and PC7 mRNA (Figure 2D) remained unchanged
in the 4-2 cells, confirming the reduction of PACE4 expression with-
out affecting the expression of other endogenous PCs. Because the
autoradiograms suggested a slight variation in the expression of these
two mRNA in the 4-2 + PACE4 cell line, we further examined these
cell lines by quantitative PCR, confirming that no significant differences
are observed.
Gene Expression Profiling in DU145 Cells
With the aim of better understanding the general contribution of
PACE4 on prostate cancer growth, we performed a comparative gene
Figure 3. Microarray analysis and real-time PCR. (A) Volcano plot of differentially expressed genes in DU145 versus 4-2 cells measured
with Illumina human expression bead chips. Vertical dashed lines show thresholds values for the fold change, whereas the horizontal
dashed line indicates the threshold value for the P value (.05). Only genes with P values higher than the threshold with a log2(fold
change) lower than −1 or higher than 1 were include in Tables W1 and W2, respectively. (B) Confirmation of values obtained with
microarrays by real-time PCR. Amplification and detection of cDNA were performed using SYBR Green I dye. The expression levels,
measured by real-time PCR (black bars), were normalized using β -actin as internal control. The white bars indicate values obtained from
microarray analyses. (C) Classification of differentially expressed genes in 4-2 cells compared with DU145 according to their biologic
processes, cellular localizations, and molecular functions. The PANTHER classification system (http://www.pantherdb.org) had no at-
tributed gene ontology grouping for nine downregulated genes and six upregulated genes.
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expression analysis by DNA microarray screening with DU145 and
4-2 cells (Figure 3A). The gene expression levels measured by micro-
arrays were validated by real-time PCR for eight genes covering a
broad range of fold changes (Figure 3B). For all the genes tested,
the quantitative PCR results (black bars) were either similar or higher
than microarray data, confirming that microarray results (white bars)
were reliable or even underestimated, at least for those tested. Of
the 38,275 genes tested, 59 genes (0.15%) showed a two-fold de-
crease, whereas 62 genes (0.16%) had a two-fold increase in 4-2 cells
(P < .05). These genes correspond to the dots found in the higher
left and right quadrants of the volcano plot, respectively (Figure 3A;
Tables W1 and W2).
The PANTHER (Protein Analysis THrough Evolutionary Relation-
ships; http://www.pantherdb.org) system was used to group the gene
listed in Tables W1 and W2 according to their biologic processes,
cellular localizations, and molecular functions using the gene ontology
classification (Figure 3C). Among the 59 downregulated and 62 up-
regulated genes, some could not be associated with any group into
the database (9 and 6, respectively), whereas the others were distrib-
uted among multiple categories in comparable proportions between
the two set of genes. Genes associated to cell communication, cellu-
lar processes (including cell cycle, cell growth, cell motion, and cell
proliferation–associated genes), developmental, and metabolic pro-
cesses are part of the major biologic functions affected by PACE4
down-regulation. The analysis of the cellular localization suggests a
central role of PACE4 into the processing of various intracellular,
membrane-bound, protein complexes and extracellular proteins. Finally,
the major molecular functions affected by PACE4 down-regulation in
4-2 cells include cellular binding, transcription regulator, and catalytic
(enzymatic) activity.
Although many of the listed genes have known biologic functions,
not all proteins encoded by these genes are known or potential PACE4
substrates. Some interesting possibilities were observed, such as the
analysis of CDH1 amino acid sequence (i.e., a cadherin) revealed that
it is a potential PACE4 substrate because it necessitates a proteolytic
processing event at the 149LRRQKR↓DW156 site of its propeptide
domain to become biologically active [50]. Moreover, PTHLH also
carries a potential PACE4 processing site at the 31SRRLKR↓AV38 of
its propeptide region [51]. However, it is not excluded that down-
regulated genes (e.g., MUC1, a known prostate cancer oncoprotein
[52]) might be indirectly affected by PACE4 expression levels without
being a direct substrate harboring a PC processing [53].
PACE4 Is Important for the Activity of Growth Factors
Considering the previous links established between PCs expression,
growth factors, and tumor progression, we measured cell proliferation
activity by generating concentrated conditioned media issued from
either untransfected DU145 or the 4-2 cell line. These growth media
were incubated with DU145 cells for 48 hours, and proliferation state
was measured by adding the MTT compound. As shown in Figure 4A,
concentrated conditioned growth medium issued from DU145 cells
(DU145 CM) stimulated the proliferation of DU145 cells in a similar
range than the complete growth medium RPMI + FBS did (OD550nm −
OD650nm = 0.44 ± 0.02 and 0.40 ± 0.02, respectively). This higher
proliferation was not measured in cells incubated with conditioned
growth medium issued from the 4-2 cell line (4-2 CM), where the
OD550nm − OD650nm value (0.31 ± 0.02) was similar to that obtained
with cells incubated with either RPMI or concentrated RPMI treated in
Figure 4. Proliferation of DU145 cells with reduced PACE4 expres-
sion. (A) MTT proliferation assay with conditioned media. DU145
cells (5.0 × 103/well in triplicate) were incubated either with RPMI,
concentrated RPMI (RPMI conc), DU145 conditioned medium
(DU145 CM), or 4-2 CM for 48 hours. After treatment, MTT solution
was added for 4.5 hours, and OD550nm − OD650nm of solubilized
cells was measured and compared using untreated cells (RPMI)
as reference. Values are mean ± SEM (n = 7). (B) Time-dependent
proliferation of untransfected DU145 cells (DU145) or expressing
tRNAVal-PACE4-SOFA-HDVRz with or without partially reestablished
PACE4 expression (4-2 and 4-2 + PACE4, respectively) was as-
sessed by counting total cell number after 24, 48, 72, and 96 hours
of incubation time. Values are mean ± SEM (n = 3). (C) Colony for-
mation after 10 days of incubation of DU145, 4-2, and 4-2 + PACE4
cell lines. Culture plates with fixed and stained cells were scanned,
and the total particle area was measured. Typical result is illustrated
for each cell line above in the upper part of the panel. The relative
total area of the transfected cell lines compared with the control cell
line is shown. Values are mean ± SEM (n = 9 for DU145 and 4-2 +
PACE4 and n = 7 for 4-2). *P < .05.
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the same way than the concentrated conditioned media, i.e., 0.28 ±
0.02 and 0.34 ± 0.03, respectively. Thus, these results suggest that
PACE4 is important for the activity of growth factors that maintain a
high proliferative status.
PACE4 Down-regulation Slows DU145 Proliferation In Vitro
To further characterize the cell proliferation reduction observed
with conditioned media experiments, we counted the total cell num-
ber of our stable cell lines at different times. As seen in Figure 4B, the
results showed a significant reduction of proliferation for the 4-2 cell
line (≈200,000 ± 10,000 cells) when compared with untransfected
DU145 (≈380,000 ± 40,000 cells) 96 hours after the initial plating.
It should be noted that these cell count experiments were carried out
in the presence of complete growth media, which includes FBS; other-
wise, the 4-2 cell line is very difficult to maintain and cell counts could
not be obtained at the 72- and 96-hour time points. The observed
reduced cell counts were partially reversed in the cell line 4-2 + PACE4
(≈280,000 ± 30,000 cells). We also performed an in vitro clonogenic
assay on the same cell lines to detect the proportion of cells that re-
tained the capacity to form colonies (Figure 4C). The results of this
assay correlate the proliferation of DU145 with PACE4 expression
levels, as we observed a 68% reduction of the colony growth in 4-2
cells when compared with wild-type DU145, whereas this colony for-
mation capacity was partially restored in 4-2 + PACE4 cells (16%
reduction when compared with the same cells).
PACE4 Inhibition Prevents Tumor Growth in Xenograft
Tumor Model
We tested the ability of our experimental cell lines to grow as tu-
mors in the nude mouse model. We injected 3 × 106 cells subcuta-
neously in nude mice flanks and measured tumor volumes 1 week
after injection. As shown in Figure 5A, the reduction of PACE4
mRNA expression level reduced dramatically the ability of the 4-2
cell line to induce tumor growth, whereas untransfected DU145 cells
were able to develop into well-defined tumor masses. After 31 days,
subcutaneous tumors were removed from nude mice for immunohis-
tochemical staining of p53, MUC1, CDK4, and PSA proteins. We
used p53 as a marker of tumoral cells because DU145 cells strongly
express a double-mutant inactive form of this protein [54]. As shown
in Figure 5 (B and C ), the tumor derived from the 4-2 cell line
contained a much lower number of tumoral cells when compared
with the tumor derived from the DU145 cell line. We confirmed
that the PSA protein was not expressed [55], and it was therefore
included as a negative control (Figure 5, H and I ). As suggested by
the comparative gene expression analysis of DU145 and 4-2 cell lines,
the 4-2 tumor showed a lower expression of the oncogene MUC1 than
those found in the DU145 tumor (Figure 5, D and E). Finally, the
staining for the CDK4 protein, a cell cycle activator, was drastically
lower in the 4-2 tumor when compared with the DU145 tumor (Fig-
ure 5, F and G), which is in agreement with the lower proliferation
rates of the 4-2 cell line described earlier (Figure 4).
Lower PACE4 Expression Induces Apoptosis in the
4-2 Cell Line
Because PACE4 expression correlated with the reduced cell prolif-
eration of DU145 cells, we decided to analyze the cell cycle of DU145,
4-2, and 4-2 + PACE4 cells by flow cytometric analysis using the PI
staining. As shown in Figure 6A, the proportion of hypodiploid cells
(characteristic of apoptotic cells) is higher in the 4-2 cell line (12.3%)
than those found either in DU145 or in 4-2 + PACE4 cells (1.74%
and 3.30%, respectively). Moreover, 78.8% of the nonapoptotic
4-2 cells were blocked into the G0/G1 phase of the cell cycle, and only
3.84% were into the G2-M phase. This is in contrast with the DU145
cells, where only 67.3% of nonapoptotic cells were in the G0-G1
phase, and 14.5% entered into the G2-M phase. However, 14.5%
of the latest cells are in the G2-M phase, whereas only 3.84% of
4-2 cells are distributed in this phase. Thus, the lower cell proliferation
observed in the 4-2 cell line can be attributed to a higher apoptosis rate
Figure 5. In vivo tumorigenicity assay and immunohistochemistry.
(A) 3.0 × 106 DU145 and 4-2 cells were subcutaneously injected in
4-week-old nu/nu female mice (two injections/mice, five mice/
group). The length and the width of the tumors were measured
three times per week for 31 days. Values shown are mean ± SEM
of tumors volumes for all tumors measured per mice group. Immu-
nohistochemical staining of tumors derived from DU145 and 4-2 cell
lines for p53 (B, C), MUC1 (D, E), CDK4 (F, G), and PSA (H, I) proteins.
All images were acquired at the same magnification (100×).
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and a blockade into the G0-G1 phase of the cell cycle. Interestingly, the
study of the partial rescue cell line 4-2 + PACE4 showed that a lower
population of these cells were in apoptosis when compared with the
4-2 cells (3.30% and 12.3%, respectively), confirming an important
role of PACE4. However, these cells with a partially restored PACE4
expression still seemed to be blocked into the G0/G1 phase of cell cycle
as for the 4-2 cells (80.6% and 78.8%, respectively) and like 4-2 cells,
the 4-2 + PACE4 cells had a low percentage of cells into the G2-M
phase (3.61%). Thus, the partial reestablishment of PACE4 expression
levels leads to a lower apoptotic percentage of DU145 cells but still
results in a partial blockade of the cell cycle into the G0/G1 phase.
Because important differences were observed between DU145 and
4-2 cell lines in regard to apoptosis, we sought potential effects on
proapoptotic factors (Figure 6B). On the type of analysis, we used
DU145 and 4-2 cell line CM digested with trypsin to perform a
MALDI-TOF/TOF analysis. One marker of interest was identified at
a mass of 1227.8Da only in the 4-2 CM. The protein identification was
then performed under the MASCOT sequence query search program
Figure 6. Cell cycle analysis and identification of an apoptotic biomarker by MALDI-TOF/TOF. (A) DNA content of DU145, 4-2 and 4-2 +
PACE4 cells was determined by flow cytometric analysis using PI staining without cell fixation. The 4-2 cells showed a higher level of
fragmented DNA than DU145 and 4-2 + PACE4 cells (12.30%, 1.74%, and 3.30%, respectively), indicating a higher population of hypo-
diploid cells for the 4-2 cell line, a characteristic of apoptotic cells. Inserts show the distribution of nonapoptotic cells into the phases of
cell cycle. (B and C) Detection and identification of the apoptotic biomarker TRPS1 were done by MALDI-TOF/TOF in positive reflectron
mode from different secretomes coming from triplicates of DU145 and 4-2 conditioned culture media after trypsin digestions. B represents
themass spectra comparison between conditioned media from both cell lines and the box shows a biomarker with a m/z of 1228 in 4-2 CM.
C shows the identification by fragmentation of this peak as the zinc finger transcription factor TRPS1 by MALDI-TOF/TOF.
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(Figure 6B). This biomarker corresponded to a fragment of the TRPS1
transcription factor, a protein issued from the apoptosis-associated
gene GC79/TRPS1 that encodes an atypical multitype zinc finger
GATA-type transcription factor associated to prostate cancer that po-
tently and specifically represses transcriptional activation mediated by
other GATA factors [56,57]. Although there is no evidence for the se-
creted release of TRPS1 or of a possible isoform, we might conclude
that its detection in CM is the result of increased apoptosis in the
4-2 cell line.
Discussion
The relationship between PCs and cancer has become stronger
within the last few years. However, because cancer cell lines generally
coexpress multiple PCs, it still remains unclear if only one or multiple
PCs are more important in cancer progression. In this study, we
chose to focus on PACE4 because of our finding that this PC is spe-
cifically overexpressed in different clinical stages of prostate cancer
tissues, arguing for a particular role of PACE4 in the establishment
or the maintenance of prostate cancer (Figure 1). To reinforce our
findings in human prostate cancer tissues, we also evaluated six inde-
pendent studies that also report the selective PACE4 overexpression
in prostate cancer (Table 1), confirming the potential importance of
this enzyme to sustain the disease.
There are various ways in which we could choose to study the role
of PACE4 in prostate cancer. Molecular and pharmacological inhibi-
tions have particular advantages, as long as they can be shown to be
specific. At the present time, molecular inhibition (gene knockout or
knockdown) is clearly more specific because pharmacological inhibi-
tors of PCs still lack PC specificity (i.e., inhibit two or more PCs
with equal potency). In regard to prostate cancer, various accepted
human model cell lines have been previously well characterized.
Therefore, for this study, we chose to establish the molecular inhibi-
tion of PACE4, using SOFA ribozyme technology, an exquisitely spe-
cific method of gene silencing, in the androgen-independent prostate
cancer cell line DU145. After PACE4-SOFA-HDVRz transfection,
a lower-than-expected number of stable cells were obtained, and
transfected DU145 cells grew very slowly. In retrospect, based on
all the evidence presented herein, this was most likely a direct con-
sequence of lowered PACE4 levels, arguing a role of PACE4 in DU145
cell proliferation.
Considering the high selectivity of PACE4-SOFA-HDVRz, we
chose the cell line with the lowest expression level of PACE4 mRNA
for further studies (Figure 2C ). Northern blots were performed for
the other endogenously expressed PCs to illustrate that this effect was
specific to PACE4 (Figure 2D). We also attempted to transfect the
cell line with the lowest PACE4 levels with an expression vector
containing the PACE4 cDNA. We were surprised to observe that
PACE4 RNA levels were reestablished because this cell line still ex-
pressed the tRNAVal-PACE4-SOFA-HDVRz (Figure 2C ). This sug-
gests that within a cellular context, the turnover rate of the ribozyme
was not as high enough to affect a much larger pool of mRNA issued
from expression vectors. Nonetheless, this partially reestablished cell
line served our purpose as a control. We believed that this was the
best control to use because it is directly derived from cells used for all
experiments, eliminating all possible cell line–to–cell line variations.
However, further improvements of the SOFA-HDVRz will eventu-
ally be required to reach higher turnover rates without significantly
affecting its specificity.
To confirm that the established 4-2 cell line with lower PACE4 ex-
pression level was a suitable model of prostate cancer, we undertook a
comparative gene expression profiling study (Figure 3). Among the
downregulated genes in the 4-2 cell line, MUC1 is the one whose ex-
pression was the most affected by the PACE4 knockdown (Table W1).
Mucin 1 is an oncoprotein expressed at high levels in diverse human
carcinoma that is implicated in cellular transformation. Indeed, by its
interactions with diverse effectors including EGFR, β-catenin, p53,
IκN kinase, and NFκB p65, MUC1 blocks the induction of apoptosis
and necrosis in human carcinoma [52,53]. A tissue microarray study
reported the overexpressed of MUC1 in 58% of human primary pros-
tate cancer tissues [58], whereas a correlation of its expression level
in human prostate carcinoma tissues with the most advance stages
of the disease was also reported [59]. The androgen-dependent pros-
tate cancer cell line LNCaP does not express MUC1, the androgen-
independent PC-3 cells expresses low constitutive levels, whereas
DU145 cells highly and constitutively express MUC1 [52,60]. Our
study now strongly correlates MUC1 expression with PACE4 expres-
sion level, as confirmed by quantitative PCR on the 4-2 cell line
(Figure 3B) and immunohistochemical staining of DU145 and 4-2
tumor xenografts (Figure 5, D and E ). Interestingly, the inhibition
of MUC1 in DU145 cells with a peptide inhibitor interfering with
its oligomerization led to similar effects than those reported in the
present study for the 4-2 cell line; that is, inhibition of cell prolif-
eration, induction of cell death pathways, and tumor regression of
DU145 xenografts growing in nude mice [52].
Some of the effects reported in the present study could be directly
linked to the reduced MUC1 expression caused by PACE4 inhibi-
tion, arguing for a central role of this overexpressed PCs in prostate
carcinoma. Although this hypothesis needs further investigation, the
study of MUC1 transcription regulators could lead to a better under-
standing of PACE4 contribution to its expression control, such as with
known transcriptional regulators of MUC1 include TNF-α, IL-6,
IFN-γ, TGF-β1, and HIF1-α [53]. In addition to TGF-β1, a known
PC substrate [26], PACE4 could also regulate MUC1 expression in-
directly by activating metalloproteinases such as ADAM17/TACE
[61], which is directly involved into the regulation of TNF-α and
IL-6 receptor [3]. Thus, considering the broad spectrum of potential
endogenous substrates of PACE4, further investigations of its direct or
indirect actions on the transcriptional control of these genes will be
needed to better understand the gene expression profile of 4-2 cells.
The consequences of lowered levels of PACE4 are well illustrated
by the reduced cell proliferation rate and the incapacity of these cells
to form subcutaneous tumors in nude mice (Figures 4 and 5, respec-
tively). The partial restoration of PACE4 expression levels in this cell
line allowed a partial recovery of the in vitro proliferation rate, sug-
gesting that PACE4 is a key player for tumoral growth and its expres-
sion levels have to be high to achieve this function (Figure 4). These
results are in great agreement with the reduced levels of the CDK4
protein in the tumor derived from the 4-2 cell line compared with
those found in the tumor derived from the DU145 cell line (Figure 5,
F and G ) because this protein is known to control the cell cycle.
Moreover, analysis of the cell cycle in the DU145, 4-2 and 4-2 +
PACE4 cell lines revealed the importance of PACE4 in regulating
apoptosis and the cell cycle (Figure 6A). These results also indicated
that partial recovery of PACE4 expression blocked DU145 apoptosis
but could not reverse the blockade of cells into the G0-G1 phase,
suggesting that full PACE4 activity is necessary to sustain the high
proliferative state of DU145 cells.
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In an attempt to identify other biomarkers affected by PACE4 in
the proliferation of DU145 cells, we undertook proteomic analyses
of DU145 and 4-2 cells derived conditioned media (Figure 6, B and
C ). In the samples issued from 4-2 cells, a fragment derived from the
tryptic digestion of TRPS1 (a multitype zinc finger GATA-type tran-
scription factor) was consistently detected [56]. This transcriptional
repressor, whose expression is regulated by androgens through the
androgen receptor, is normally expressed in the androgen-dependent
LNCaP prostate cancer cells [62,63]. Its lack of expression has been
previously reported for the androgen-independent DU145 prostate
cancer cells [62], but the stable expression of recombinant TRPS1
in those cells allowed identification of both downregulated antiapop-
totic protein POR2 and upregulated proapoptotic protein KAD2
[64]. Our data demonstrate that PACE4 can regulate the expression
of the proapoptotic factor TRPS1. Further studies will be required to
better characterize the involvement of PACE4 into the transcriptional
control of the TRPS1 transcriptional repressor. As mentioned earlier,
TRPS1 transcription is known to be regulated by androgens in cells
LNCaP prostate cancer cells but not in the DU145 cell line, whose
growth is independent of androgens and does not express the androgen
receptor [62]. Recently, the bone morphogenic protein 7 (BMP-7), a
growth factor belonging to the family of TGF-β that requires a PC
cleavage for its propeptide removal [65], has been identified as an in-
ducer of TRPS1 gene expression in mouse kidneys [66]. Thus, fur-
ther characterization of the TRPS1 genetic regulation by BMP-7 in
DU145, or other members of the TGF-β growth factor family that
also need furin-like cleavages for processing [3], would be indicated
to better understand the cellular functions of the overexpressed PACE4
in human prostate cancer cells.
The genes known to be transcriptionally regulated by TRPS1 in-
clude PSA [63], STAT3 [67], parathyroid hormone-related protein
(PTHrP) [68], and osteocalcin [69]. Interestingly, the cleavage of
human PTHrP and osteocalcin propeptides, essential for the gener-
ation of their mature forms, occurs at typical PCs processing sites
(31SRRLKR↓AV38 and 46VKRPRR↓YL51, respectively). Thus, the
implication of PACE4 catalytic activity to the transcriptional control
of TRPS1 and DU145 apoptosis triggering could be through these
potential substrates. This hypothesis is supported by our genomic
analysis, where the gene PTHLH (coding for PTHrP) was upregu-
lated in 4-2 cells (Table W2).
Regarding the potential therapeutic avenues targeting PACE4,
these include various approaches such as small molecule inhibitors
[28], monoclonal antibodies [70], or even ribozymes or siRNA com-
plexed with liposomes [71]. Small molecule inhibitors may be prob-
lematic because none of these have been shown to be specific to
a particular PC. This is due to the high similarity of the catalytic
regions of each PC. Whereas monoclonal antibodies could provide
better specificity, it is not clear whether PACE4 localized at the cell
surface and/or intracellular PACE4 will require targeting [72]. Fi-
nally, ribozyme or siRNA complexed with liposomes would certainly
be highly specific but require additional research to make these re-
agents druggable. One potential avenue of research that offers both
specificity and cell compatible characteristics (i.e., little toxicity and
cell permeability) is the development of small peptide inhibitors
(∼1000 Da) targeting PACE4 [9]. Combined with peptidomimetics,
such studies could lead to the development of novel drugs for pros-
tate cancer.
In conclusion, this study reports the specific overexpression of
PACE4 in prostate cancer tissues. Our results showed that PACE4
plays a major role in the progression of prostate tumors to a higher
aggressive status, and its inhibition leads to a significant loss of
tumorigenicity of the prostate tumor cell line DU145. A better un-
derstanding of PACE4 direct and indirect cellular targets contribut-
ing to these phenomena remains a great challenge and implicates
multiple known oncogenic factors. Nonetheless, the data strongly
validate PACE4 as an important therapeutic target in human pros-
tate cancer.
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Table W1. Downregulated Genes in 4-2 Cells Compared to DU145.
Accession Numbers Gene Symbol Gene Description Fold Change DU145 vs 4-2 P
NM_002456 MUC1 Mucin 1 0.080 .00123
NM_030631 SLC25A21 Solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21 0.118 .00037
NM_021034 IFITM3 Interferon-induced transmembrane protein 3 (1-8U) 0.121 .00038
NM_006435 IFITM2 Interferon-induced transmembrane protein 2 (1-8D) 0.142 .00109
NM_004613 TGM2 Transglutaminase 2 0.182 .00043
NM_013230 CD24 CD24 0.184 .02952
NM_019601 SUSD2 Sushi domain containing 2 0.186 .01475
NM_004657 SDPR serum deprivation response 0.209 .01243
XM_938803 CST6 Cystatin E/M 0.282 .02171
NM_052886 MAL2 mal, T-cell differentiation protein 2 0.302 .00003
NM_001430 EPAS1 Endothelial PAS domain protein 1 0.313 .00121
NM_000101 CYBA Cytochrome b-245, α polypeptide 0.314 .02607
NM_001038 SCNN1A Sodium channel, non–voltage-gated 1α 0.317 .00156
NM_032899 FAM83A Family with sequence similarity 83, member A 0.319 .00745
NM_000211 ITGB2 Integrin, β2 0.324 .00416
NM_001386 DPYSL2 Dihydropyrimidinase-like 2 0.325 .00857
NM_003280 TNNC1 Troponin C type 1 (slow) 0.328 .03211
NM_001823 CKB Creatine kinase, brain 0.347 .01088
NM_174911 FAM84B Family with sequence similarity 84, member B 0.353 .00069
NM_001793 CDH3 Cadherin 3 0.354 .00003
NM_007257 PNMA2 Paraneoplastic antigen MA2 0.358 .00459
NM_021135 RPS6KA2 Ribosomal protein S6 kinase 0.367 .00103
NM_020859 SHRM Shroom 0.369 .00973
NM_199001 MGC59937 Similar to RIKEN cDNA 2310002J15 gene 0.374 .00505
NM_001003794 MGLL Monoglyceride lipase 0.375 .00604
NM_003246 THBS1 Thrombospondin 1 0.394 .03839
NM_004360 CDH1 Cadherin 1 0.399 .00005
NM_002754 MAPK13 Mitogen-activated protein kinase 13 0.400 .00182
NM_002354 TACSTD1 Tumor-associated calcium signal transducer 1 0.402 .00197
NM_173584 MGC45840 EF-hand calcium binding domain 4A 0.406 .00659
AK027147 HS.509165 cDNA: FLJ23494 fis, clone LNG01885 0.407 .00691
NM_014578 RHOD ras homolog gene family, member D 0.409 .00604
NM_182498 C19ORF37 Zinc finger protein 428 0.416 .00178
XM_051862 LOC58489 Hypothetical protein from EUROIMAGE 588495 0.416 .02740
NM_020210 SEMA4B Semaphorin 4B 0.417 .02468
NM_020770 CGN Cingulin 0.419 .04416
NM_024329 EFHD2 EF-hand domain family, member D2 0.430 .00365
NM_019058 DDIT4 DNA-damage-inducible transcript 4 0.431 .03417
NM_024830 AYTL2 Acyltransferase like 2 0.437 .00391
NM_198282 TMEM173 Transmembrane protein 173 0.437 .00316
NM_005630 SLCO2A1 Solute carrier organic anion transporter family, member 2A1 0.437 .00219
NM_015055 SWAP70 SWAP-70 protein 0.442 .00778
NM_021101 CLDN1 Claudin 1 0.443 .01301
NM_017917 PPP2R3C Protein phosphatase 2, regulatory subunit B″, γ 0.444 .00839
NM_005195 CEBPD CCAAT/enhancer binding protein 0.457 .03235
NM_018478 C20ORF35 Chromosome 20 open reading frame 35 0.461 .01029
NM_021818 SAV1 Salvador homolog 1 0.467 .00302
NM_000600 IL6 Interleukin 6 0.467 .04991
NM_014220 TM4SF1 Transmembrane 4 L six family member 1 0.479 .00002
BU536065 HS.579631 cDNA clone IMAGE: 6563923 5, mRNA sequence 0.485 .03222
NM_003475 RASSF7 Ras association (RalGDS/AF-6) domain family 7 0.488 .00515
NM_001013398 IGFBP3 Insulin-like growth factor binding protein 3 0.490 .02959
NM_025151 RAB11FIP1 RAB11 family interacting protein 1 (class I) 0.490 .04771
NM_033317 ZD52F10 Dermokine 0.493 .00677
NM_001993 F3 Coagulation factor III 0.494 .00051
NM_006169 NNMT Nicotinamide N -methyltransferase 0.495 .00990
NM_003726 SCAP1 src family associated phosphoprotein 1 0.496 .00242
XM_944693 ITGB5 Integrin, β5 0.496 .00388
NM_018098 ECT2 Epithelial cell- transforming sequence 2 oncogene 0.498 .00104
Table W2. Upregulated Genes in 4-2 Cells Compared to DU145.
Accession Numbers Gene Symbol Gene Description Fold Change DU145 vs 4-2 P
NM_006216 SERPINE2 Serpin peptidase inhibitor, clade E, member 2 5.140 .02748
NM_005242 F2RL1 Coagulation factor II (thrombin) receptor-like 1 5.119 .00063
NM_014689 DOCK10 Dedicator of cytokinesis 10 4.418 .00296
NM_178012 TUBB2B Tubulin, β2B 4.330 .00075
NM_024101 MLPH Melanophilin 4.310 .00118
NM_003937 KYNU Kynureninase 3.722 .03011
NM_002281 KRTHB1 Keratin 81 3.623 .01352
NM_003739 AKR1C3 Aldo-keto reductase family 1, member C3 3.488 .00293
NM_177949 ARMCX2 Armadillo repeat containing, X-linked 2 3.079 .00010
NM_002522 NPTX1 Neuronal pentraxin I 2.988 .00034
NM_024016 HOXB8 Homeo box B8 2.911 .00218
NM_000104 CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 2.866 .00415
NM_002380 MATN2 Matrilin 2 2.854 .00584
NM_000165 GJA1 Gap junction protein, α1 2.833 .00032
NM_020299 AKR1B10 Aldo-keto reductase family 1, member B10 2.830 .00556
NM_153344 C6ORF141 Chromosome 6 open reading frame 141 2.727 .01479
NM_002228 JUN jun oncogene 2.655 .00128
NM_004163 RAB27B Clone 25194 mRNA sequence 2.615 .01647
NM_004398 DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 2.593 .00221
NM_000782 CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 2.504 .00226
NM_001259 CDK6 Cyclin-dependent kinase 6 2.461 .00582
NM_020919 ALS2 Amyotrophic lateral sclerosis 2 (juvenile) 2.439 .00248
NM_001964 EGR1 Early growth response 1 2.438 .01511
AF131834 HS.4892 Clone 24841 2.428 .00563
NM_003543 HIST1H4H Histone cluster 1, H4h 2.413 .01138
NM_002639 SERPINB5 Serpin peptidase inhibitor, clade B, member 5 2.406 .00149
NM_012419 RGS17 Regulator of G-protein signaling 17 2.351 .01676
NM_032784 RSPO3 R-spondin 3 homolog 2.348 .03649
XM_928153 LOC653571 Similar to sperm protein associated with the nucleus, X chromosome, family member B1 2.329 .00901
NM_002737 PRKCA Protein kinase C, α 2.326 .00476
NM_001001390 CD44 CD44 molecule (Indian blood group) 2.306 .01926
XM_940680 LOC648517 Similar to aldo-keto reductase family 1 member C1 2.269 .01923
NM_003528 HIST2H2BE Histone cluster 2, H2be 2.264 .00707
NM_003714 STC2 Stanniocalcin 2 2.261 .02278
NM_012242 DKK1 Dickkopf homolog 1 2.249 .00873
NM_020547 AMHR2 Anti-mullerian hormone receptor, type II 2.213 .00011
AK091904 HS.202577 cDNA FLJ34585 fis, clone KIDNE2008758 2.202 .00825
NM_198966 PTHLH Parathyroid hormone-like hormone 2.200 .00008
NM_015508 TIPARP TCDD-inducible poly(ADP-ribose) polymerase 2.190 .02173
NM_001236 CBR3 Carbonyl reductase 3 2.175 .00163
NM_001387 DPYSL3 Dihydropyrimidinase-like 3 2.165 .01420
NM_025145 C10ORF79 Chromosome 10 open reading frame 79 2.158 .00026
NM_001889 CRYZ Crystallin, zeta (quinone reductase) 2.151 .01170
NM_004403 DFNA5 Deafness, autosomal dominant 5 2.141 .00460
NM_005319 HIST1H1C Histone cluster 1, H1c 2.110 .00689
NM_001878 CRABP2 Cellular retinoic acid binding protein 2 2.094 .01508
NM_001010924 C10ORF38 Chromosome 10 open reading frame 38 2.092 .00581
NM_000475 NR0B1 Nuclear receptor subfamily 0, group B, member 1 2.084 .00179
NM_004615 TSPAN7 Tetraspanin 7 2.084 .00504
NM_000358 TGFBI Transforming growth factor, β-induced 2.057 .02546
NM_005329 HAS3 Hyaluronan synthase 3 2.051 .03194
NM_032168 WDR75 WD repeat domain 75 2.020 .01148
NM_001008490 KLF6 Kruppel-like factor 6 2.018 .00732
NM_006120 HLA-DMA Major histocompatibility complex, class II, DM α 2.018 .02250
XM_937100 KRTAP2-1 Keratin-associated protein 2-1 2.013 .01978
NM_002178 IGFBP6 Insulin-like growth factor binding protein 6 2.009 .01644
NM_005682 GPR56 G protein–coupled receptor 56 2.009 .01484
NM_006307 SRPX Sushi-repeat–containing protein, X-linked 2.009 .00006
NM_002147 HOXB5 Homeo box B5 2.006 .00202
NM_015642 ZBTB20 Zinc finger and BTB domain containing 20 2.005 .01040
NM_020411 XAGE1 X antigen family, member 1D 2.002 .02842
NM_016352 CPA4 Carboxypeptidase A4 2.000 .03194
